Abstract:Lisda Amalia Department of Neurology, The First Affiliated Hospital of Faculty of Medicine, Universitas Padjadjaran/RSUP dr. Hasan Sadikin, Bandung, Indonesia Correspondence: Lisda Amalia Jl.Pasteur 38, Bandung, 40161, Indonesia Email Introduction: Blockage of the cerebral arteries due to thrombosis and embolism resulting in decreased blood flow to the brain, reduced oxygen supply to the brain, resulting in neuronal damage and causes astrocyte cells to secrete glial fibrillary acidic protein (GFAP). The objective of this study was to determine the correlation between GFAP levels serum and clinical outcome in patients with acute ischemic stroke. Methods: This was observational with a cross-sectional design on acute ischemic stroke patients confirmed by CT scans and divided into large vessel occlusion and small-vessel occlusion. Clinical outcome was measured using the National Institutional Health Stroke Scale (NIHSS) tool. Statistical analysis uses Spearman's rank correlation test and Mann Whitney's test, significant if p < 0.05. Results: After collecting 33 research subjects, we found 16 people with large vessel occlusion and 17 people with small vessel occlusion. Serum GFAP levels were 0.2– 1.9 ng/mL, 9.1% with a mild neurological deficit, 45.45% were moderate neurological deficits, and 45.45% were severe neurological deficits. There was a significant positive correlation (r = 0.522; p = 0.002) between serum GFAP levels and the degree of neurological deficit in ischemic stroke patients. There was a statistically significant difference between serum GFAP levels in ischemic stroke patients with CT scan results of large artery occlusion compared to small artery occlusion (0.7 vs 0.4ng/mL; p = 0.001). Conclusion: There was a positive correlation between GFAP level serum and NIHSS score on acute ischemic stroke. The higher the value of GFAP serum level, the higher the value for NIHSS and correlated with stroke severity and the extent of brain damage in ischemic stroke patients. Keywords: GFAP, clinical outcome, acute ischemic stroke, small vessel occlusion, large vessel occlusion Stroke is a neurological emergency that arises suddenly and is the 3rd cause of death in the world after heart disease and cancer. 1 Ischemic stroke is the most common type of stroke, accounting for 87% of all strokes worldwide. Impaired blood-brain barrier permeability causes GFAP to diffuse into the cerebrospinal fluid and then enter the blood circulation to detect GFAP levels in the blood. GFAP levels can begin to be detected in the blood after 12 hours of the onset of ischemic stroke and reach the highest levels after 48 hours of the onset of ischemic stroke. 2,3 There is hyperreactivity of astrocytes as a result of glutamate excitotoxicity, which can cause changes in astrocytes, namely astrocytes experience hypertrophy and proliferation which is referred to as the astrogliosis process in acute ischemic stroke. Prolonged astrogliosis in patients with brain ischemia can increase neuronal death and exacerbate brain tissue degeneration. This astrogliosis process is characterized by a rapid and high increase in GFAP levels because damaged astrocytes secrete GFAP. Astrocytes are cells that make up the blood-brain barrier, so if there is damage to the blood-brain barrier, it will cause GFAP levels to increase and enter the bloodstream. 4 GFAP level serum can be used to assess neurologic deficits, monitor therapy, and prognosticate ischemic stroke. In ischemic stroke, the greater the damage to neurons and neuroglia, the serum GFAP levels will increase, and there is a relationship between high GFAP levels and the severity of the neurological deficit and the extent of brain damage in ischemic stroke patients. The larger the infarct area, the higher the serum GFAP level and NIHSS score. 3 Based on the above framework, this study aims to determine the correlation between serum GFAP levels and clinical outcomes based on the NIHSS score in ischemic stroke patients. It was an observational correlative analysis with a cross-sectional design at RSUP. Dr. Hasan Sadikin from June 2015 to November 2015. The research subjects were patients diagnosed with ischemic stroke confirmed by CT scan who came to the hospital within five days after stroke onset and were grouped into large vessel occlusion and small-vessel occlusion based on clinical symptoms and imaging. We exclude the presence of a history of previous stroke, head trauma, patients with glioblastoma multiforme. The results of the NIHSS criteria assessment are scores, namely a score of 12 indicating a severe neurological deficit. Examination -Abstract Truncated-

Serum Glial Fibrillary Acidic Protein : Potential To Determine Stroke-Type, Time-Line and Tissue-Impact In Acute Stroke

Serum glial fibrillary acidic protein in acute stroke: feasibility to determine stroke-type, timeline and tissue-impact

The Predictive Value of Serum F-actin on the Severity and Early Neurological Deterioration of Acute Ischemic Stroke: PREDICTIVE VALUE OF F-ACTIN IN STROKE

Incremental value of serum neurofilament light chain and glial fibrillary acidic protein as blood-based biomarkers for predicting functional outcome in severe acute ischemic stroke

Serum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke

The Importance of Increased Serum GFAP and UCH-L1 Levels in Distinguishing Large Vessel from Small Vessel Occlusion in Acute Ischemic Stroke

Glial Fibrillary Acidic Protein Serum Level as a Predictor of Clinical Outcome in Ischemic Stroke

Abstract 57: Rapid Prehospital Diagnosis of Intracerebral Hemorrhage by Measuring GFAP on a Point-of-Care Platform

Expression of Acidic Fibrillar Protein and Neuroglobin in Thrombolytic Patients in Ischemic Stroke

Diagnostic Accuracy of Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-Terminal Hydrolase-L1 Serum Concentrations for Differentiating Acute Intracerebral Hemorrhage from Ischemic Stroke

Plasma Glial Fibrillary Acidic Protein (GFAP) as a Biomarker of Acute Focal Brain Injury

Neuronal plasma biomarkers in acute ischemic stroke

Biomarkers for acute diagnosis and management of stroke in neurointensive care units

Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke

Blood-based protein biomarkers during the acute ischemic stroke treatment window: a systematic review

Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes

Dynamic changes and its clinical significance of serum glial fibrillary acidic protein content in patients with acute cerebral infarction

Reflections on the Clinical Implications of Glial Fibrillary Acidic Protein and Neuroglobin in Ischemic Stroke

A comprehensive Exdia TRF-LFIA for simultaneous quantification of GFAP and NT-proBNP in distinguishing ischemic and hemorrhagic stroke

Blood biomarkers in the early stage of cerebral ischemia

Abstract WP275: Longitudinal Biomarker Analysis in Patients With Ischemic Stroke: Exploratory Targeted and Omics Assessments From a Phase 2a Clinical Trial